Related Experiment Videos

[Evidence and consensus based treatment guidelines 2010 for juvenile idiopathic arthritis by the German Society of

G Dueckers1, N Guellac, M Arbogast

  • 1Zentrum für Kinder- und Jugendmedizin, HELIOS Klinikum Krefeld.

Klinische Padiatrie
|October 21, 2011
PubMed

Insights

Updated guidelines for Juvenile Idiopathic Arthritis (JIA) treatment are established. These evidence-based recommendations incorporate recent research to enhance care for children and adolescents with JIA.

Area of Science:

  • Rheumatology
  • Pediatrics
  • Evidence-Based Medicine

Background:

  • Juvenile Idiopathic Arthritis (JIA) treatment has advanced, improving quality of life for affected children and adolescents.
  • Standardizing care is crucial for optimizing treatment outcomes in JIA patients.
  • Recent research necessitates an update to the existing 2007 JIA treatment guidelines.

Framework:

  • A systematic literature review of clinical trials published within the last 3 years was conducted.
  • Key terms included juvenile idiopathic arthritis, therapy, humans, and pediatric populations (0-18 years).
  • Studies on JIA diagnosis, uveitis, vaccination, and transition were excluded to focus on treatment.

Implementation:

  • Representatives from major pediatric and rheumatology societies participated in consensus conferences.
  • Consensus statements were developed using nominal group technique and the Delphi method.
  • Over 95% of nominated representatives attended the consensus conferences, ensuring broad input.

Implications:

  • Updated consensus statements address drug therapy, symptomatic management, and surgical interventions for JIA.
  • The recommendations adhere strictly to the principles of Evidence-Based Medicine (EBM).
  • These updated guidelines aim to standardize and improve the quality of care for pediatric JIA patients.
Abstract

Related Concept Videos

Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...